Key facts
- CancerIQ has added the geneType Cancer Risk Assessment from Rhythm Biosciences to its platform.
- The geneType test is now available for clinical ordering across CancerIQ's network.
- CancerIQ's network includes more than 60 health systems.
CancerIQ announced on June 2, 2026, that the geneType™ Cancer Risk Assessment from Rhythm Biosciences is now available on the CancerIQ platform. This integration allows healthcare providers within CancerIQ's network of over 60 health systems to order the geneType™ test for their patients. The geneType™ test is designed for cancer risk assessment, expanding the suite of diagnostic tools accessible through the CancerIQ platform.